

Women's Health Initiative Sample Application Applicant Name (Organization) (required) Select... This will automatically be blinded to reviewers. Non-Profit Principal Investigator (required) First Name Last Name This will automatically be blinded to reviewers. Title of Non-Profit Principal Investigator (required) This will automatically be blinded to reviewers. Email of Non-Profit Principal Investigator (required) email@example.com This will automatically be blinded to reviewers. Phone of Non-Profit Principal Investigator (required) This will automatically be blinded to reviewers. Authorized Representative (required) Last Name This will automatically be blinded to reviewers. Title of Authorized Representative (required) This will automatically be blinded to reviewers. Email of Authorized Representative (required) email@example.com This will automatically be blinded to reviewers. Address of Non-Profit Entity (required) This will automatically be blinded to reviewers. City/Town of Non-Profit Entity (required)

Zip Code of Non-Profit Entity (required)

This will automatically be blinded to reviewers.

Sel	ect •
This	will automatically be blinded to reviewers.
Nan	ne of Press Contact (required)
	Name Last Name will automatically be blinded to reviewers.
Ema	ail Address of Press Contact (required)
ema	ail@example.com
This	will automatically be blinded to reviewers.
Pres	ss Contact Telephone (required)
	
Γhis	will automatically be blinded to reviewers.
	ease Focus Area site their prevalence and profound impact on quality of life, pregnancy-induced hypertension and perimenopause/menopause remain vastly under-
esea	arched and poorly understood. This round's disease focus areas aim to reverse that trend by investing in targeted science, coordinated strategy, and
susta	ined collaboration.
A //-	
VV 110	at is the primary disease focus area of this project? (required)
\bigcirc	Pregnancy-Induced Hypertension
\bigcirc	Perimenopause/Menopause
	ar Selection
to ac	icants will join one of the four pillar-based research teams within their disease focus area. These interdisciplinary teams will work in a coordinated fashion celerate understanding, innovation, and implementation to ensure that progress in one area informs and amplifies others. Although grants are awarded
direc	tly to institutions, funded projects are not isolated efforts but are part of a coordinated ecosystem.
Wha	at is the primary pillar of this project? (required)
С	Al & Data Science: Harnessing the power of artificial intelligence, predictive modeling, and big data to identify patterns, improve diagnosis, and uncover new research questions.
\subset	Disease Biology: Investigating the fundamental mechanisms of disease, including hormonal, genetic, and molecular drivers, to build a foundation for targeted therapies.
\subset	R&D: Advancing preclinical and translational research aimed at developing novel diagnostics, interventions, and therapeutic strategies.
\supset	Clinical Adoption: Bridging research and practice by identifying pathways to integrate discoveries into clinical settings and improve patient outcomes.
Nha	at other pillars may this project align to, if any?
	Al & Data Science: Harnessing the power of artificial intelligence, predictive modeling, and big data to identify patterns, improve diagnosis, and uncover new research questions.
	Disease Biology: Investigating the fundamental mechanisms of disease, including hormonal, genetic, and molecular drivers, to build a foundation for targeted therapies.

A B C D E Co-Principal Investigator (Co-Pl) Name Co-Pl Title Organization Name Organization Location Co-Pl E-Mail Address Co-Pl Title Organization Name Organization Location Co-Pl E-Mail Address		R&D: Advancing preclinical and translation	al research aimed at devel	oping novel diagnostics, into	erventions, and therapeutic s	trategies.
an effort to review all applications, based solely on the merits of the proposal and qualifications of the team, the MLSC will blind the identifies of research teambers to reviewers during the review process. Den-Profit PI Lead Name (required) at name Last name is will automatically be blinded to reviewers. Den-Profit PI Title and Department (required) Den-Profit PI Institution (required) Den-Profit PI I		Clinical Adoption: Bridging research and p	ractice by identifying pathv	vays to integrate discoverie	s into clinical settings and imp	prove patient outcomes.
St name Last name is will automatically be blinded to reviewers. Den-Profit PI Title and Department (required) Den-Profit PI Institution (required) Delect Seem of PI's relevant experience, without identifying him/her by name or gender, (required) Limit 500 wc Deseroin to which have included small clinical titles. The PI's the research group leader with expertise in the areas of XYZ Deseroin Team Members A B C D E Co-Principal Investigator (Co-PI) Name Co-PI Title Organization Name Organization Location Co-PI E-Mail Address Co D C D C D C D C D C D C D C D C D C D	an e	ffort to review all applications, based solely		osal and qualifications of the	e team, the MLSC will blind th	ie identities of research tea
Son-Profit PI Title and Department (required) con-Profit PI Institution (required) con-Profit PI Instituti	on-l	Profit PI Lead Name (required)				
Son-Profit PI Title and Department (required) con-Profit PI Institution (required) con-Profit PI Instituti						
pon-Profit PI Institution (required) select is will automatically be blinded to reviewers. sescribe the PI's relevant experience, without identifying him/her by name or gender. (required) Limit: 500 w. Limit:						
is will automatically be blinded to reviewers. Sescribe the Pl's relevant experience, without identifying him/her by name or gender. (required) Limit: 500 wc. Limit: 500 w	on-	Profit PI Title and Department (rec	uired)			
is will automatically be blinded to reviewers. Sescribe the Pl's relevant experience, without identifying him/her by name or gender. (required) Limit: 500 wc. Limit: 500 w						
Limit: 500 w. Limit:						
Limit: 500 wo lessed don't use PI's name or gendered pronouns (he/him/his or she/her/hers). Ex. The PI has 10 years of experience administering and managing projects, weral of which have included small clinical trials. The PI is the research group leader with expertise in the areas of XYZ Besearch Team B C D E Co-Principal Investigator (Co-Pi) Name Co-PI Title Organization Name Organization Location Co-PI E-Mail Address Co-PI E-Mail Address Co-PI E-Mail Address Double CO-PRINCIPAL INVESTIGATOR(S), provide information on them in the table. This field will automatically be blinded to reviewers.						•
Limit: 500 wc ease don't use PI's name or gendered pronouns (he/him/his or she/her/hers). Ex. The PI has 10 years of experience administering and managing projects, weral of which have included small clinical trials. The PI is the research group leader with expertise in the areas of XYZ Sesearch Team Members A B C D E 1 Co-Principal Investigator (Co-PI) Name Co-PI Title Organization Name Organization Location Co-PI E-Mail Address 2 3 4 5 5 5 5 6 6 7 7 8 8 8 8 8 9 8 9 9 9 9 9 9 9 9 9 9 9	15 ***	in date matically be billided to reviewers.				
esearch Team Members A B C D E 1 Co-Principal Investigator (Co-PI) Name Co-PI Title Organization Name Organization Location Co-PI E-Mail Address 2 3 4 9 90 90 90 90 90 90 90 90 90 90 90 90 9		dollars Dispose or condered account	s /ho/him/his or sho/hor/ho	vr) Fy The Dibas 40 years	of augustance administration	Limit: 500 wo
A B C D E 1 Co-Principal Investigator (Co-PI) Name Co-PI Title Organization Name Organization Location Co-PI E-Mail Address 2 Organization Name Organization Location Co-PI E-Mail Address 3 Organization Name Organization Location Co-PI E-Mail Address 4 Organization Name Organization Location Co-PI E-Mail Address			•	•		and managing projects,
A B C D E 1 Co-Principal Investigator (Co-PI) Name Co-PI Title Organization Name Organization Location Co-PI E-Mail Address 2 3 4 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	ese	arch Team				
1 Co-Principal Investigator (Co-PI) Name Co-PI Title Organization Name Organization Location Co-PI E-Mail Address 2 3 4 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	ese	arch Team Members				·
2 3 4 You have CO-PRINCIPAL INVESTIGATOR(S), provide information on them in the table. This field will automatically be blinded to reviewers.		А	В	С	D	Е
3 4 Frou have CO-PRINCIPAL INVESTIGATOR(S), provide information on them in the table. This field will automatically be blinded to reviewers.	1	Co-Principal Investigator (Co-PI) Name	Co-PI Title	Organization Name	Organization Location	Co-PI E-Mail Address
rou have CO-PRINCIPAL INVESTIGATOR(S), provide information on them in the table. This field will automatically be blinded to reviewers.	3					
	4					
you have co-PI(s), describe their relevant experience without identifying them by name or gender.	you l	nave CO-PRINCIPAL INVESTIGATOR(S), pr	ovide information on them	in the table. This field will au	utomatically be blinded to rev	riewers.
	yοι	ı have co-PI(s), describe their rele	evant experience with	nout identifying them	by name or gender.	

		-			sne/ner/ners). Ex. The co-F search group leader with			mmstel	ring and managing projects
oro	posal to MLSC								
lav	e you been awarde	d an	MLSC grant in the pa	ast? (required)				
)	Yes								
)	No								
th	nis application a con	nplete	ely new project or a	follov	w-on to a prior MLSC	gran	t? (required)		
)	New project proposal								
)	Follow-on proposal to p	orior Ml	_SC grant						
. Pı	roposal Title (required	i)							
Vha	at disease(s) and co	nditio	on(s) does this projec	ct pri	marily study? Please	choo	se up to three opti	ons. (re	equired)
	Autoimune Disorders		Cancer - Breast		Cancer - Others		Cancer - Ovarian		Cardiology/ Cardiovascular Research
	Chronic Illness/Disease		Endocrinology		Environmental Health		Gastrointestinal (GI)		Geriatrics & Gerontology
	Hematology		Immunology/Inflamm ation		Infectious Diseases		Liver		Maternal/Infant Health
	Metabolic Diseases		Microbiome		Neuroscience		Nutritional Science		Oral Health
	Orthopedic Research		Pediatric Research		Psychiatry/ Mental Health		Public Health/ Epidemiology		Rare Diseases
	Regenerative Medicine		Reproductive Health		Toxicology		Women's Health/ Gender Studies		Other
	N/A								
∕Vha	at modality/modaliti	es do	es your project prim	arily	employ? Please cho	ose u	p to three options.	(require	ed)
	Cell & Gene Therapy		Clinical Trials		Data Science		Diagnostics		Digital Health
	Drug Delivery		Drug Discovery & Development		Imaging		Medical Device		mRNA/siRNA/ RNA Research
	Personalized/Precisio n Medicine		Phototherapy		Radiation Therapy		Robotics		Vaccines
	Other		N/A						
Wha	at are tools and tech	nniqu	es used in your proj	ect? I	Please choose up to	three	options. (required)		
	3D printing		AI/ML/Deep Learning		Antibody		Automation		Biomanufacturing
_	Biomarker		Biomaterials/ Material		Rioconcor		Contract Work-		Crystallography/
	Identification		Sciences		Biosensor		CRO/CDMO/CMO		Peptide synthesis

	CT/MRI		Data Optimization				Record (FMR)		
	FACS/ Flow Cytometry		Genome Editing		Genomics		In Vitro cultures		In Vivo animal models
)	Liquid Chromatography		Mass Spectroscopy		Metabolomics		Microscopy		Nanotechnology
)	Next-generation Sequencing		NMR/MRS		Organoid/ Organ-on- a-chip		Pasteurization/ Sterilization		Patient Avatars
	Proteomics		Small Molecule		Software & Algorithms		Transcriptomics		Ultrasound
	Viral Vector		Other		N/A				
2. Ir	ı lay terms, summa	arize yo	our project in 3-5 se	entenc	es intended for a br	oad a	udience. (required)		
									,
									Limit: 250 words
3. D	escribe the clinica	ıl/scien	tific need or proble	m the	project seeks to ad	dress	. (required)		
									Limit: 150 words
1. D	escribe the currer	nt solut	ion. (required)						
5. D		sed pro		timeli	ne, specific milestor	nes ar	nd detailed activities	s you	
5. D	escribe the propo	sed pro		timeli	ne, specific milestor	nes ar	nd detailed activities	s you	plan to accomplish
5. D with	escribe the propo MLSC funding. (re	sed pro equired)	oject, including the	les on					plan to accomplish
5. D with	escribe the propo MLSC funding. (re	sed pro equired)	oject, including the	les on					plan to accomplish Limit: 500 words
5. D with	escribe the propo MLSC funding. (re	sed proequired)	oject, including the approval and sampl llaborators. (required)	les on		e outli	ne the anticipated t	ime to	Limit: 500 words
5. D with	escribe the propo MLSC funding. (re	sed proequired)	oject, including the approval and sampl llaborators. (required)	les on	hand? If not, please	e outli	ne the anticipated t	ime to	Limit: 150 words
5. D with	escribe the propo MLSC funding. (re	sed proequired)	oject, including the approval and sampl llaborators. (required)	les on	hand? If not, please	e outli	ne the anticipated t	ime to	Limit: 500 words acquire and note if Limit: 150 words

differences be reported? Please list which factors will be studied. If none are studied, please explain why. (required)

	Limit: 150 word
. Have you generated any IP to date? (required)	
ion't use PI's name in this section.	Limit: 75 word
O. What is the specific outcome of the proposed project (i.e. publication of papers, filing of IP, securing IP, for company, etc.)? How will this move the technology closer to translation or commercialization? (required)	ormation of a
Company, See, From the and the analysis of the see, and the see of the	
	Limit: 250 word
1. What academic and/or industry partners are working with you on the project? What is their role? (required)	
	Limit: 150 wor
2. What are the key challenges to successful translation of the technology and how do you plan to overcom	e them? (required
	Limit: 250 word
3. Please describe how will you make equipment and/or data purchased under this grant publicly available.	(required)
	Limit: 150 wor
	Lillit. 130 Wol
4. Describe the impact of your proposed project on Massachusetts (in the context of local business or resear partnerships, local purchasing, local prototyping, patients, jobs etc.). (required)	arch
	Limit: 150 wor
	Lillit. 130 Wol
CITATION LIST - end of the proposal section	
you reference research or statistics, please provide a citation to identify the source of the information. You will be given the option to inpublic up the used any, in the order they appear in the application at the end of this section (Question 16).	ut your references if
TITATIONS ARE OPTIONAL	
5. Enter citations in the order that they appear in your application. Please do NOT mention the PI's name.	

Limit: 600 characters

6. Who are the other investigators in th	ne Massachusetts ecosystem that you intend to collaborate with to advance this pilla
	a)? How will you together advance our knowledge of this space? (required)
	Limit: 150 wo
7. Letters of Commitment from partner	s providing financial or in-kind support for the work.
	Choose File
	Choose File
elect up to 5 files to attach. No files have been att	
cceptable file types: .pdf	
cceptable file types: .pdf or any partners providing financial or in-kind supp	ached yet. You may add 5 more files. ort for the work, please upload letters of commitment in PDF format outlining their commitment. DO NOT
cceptable file types: .pdf or any partners providing financial or in-kind supp	ached yet. You may add 5 more files. ort for the work, please upload letters of commitment in PDF format outlining their commitment. DO NOT
cceptable file types: .pdf or any partners providing financial or in-kind supp	ached yet. You may add 5 more files. ort for the work, please upload letters of commitment in PDF format outlining their commitment. DO NOT
cceptable file types: .pdf or any partners providing financial or in-kind supp ENTION THE PI BY NAME OR GENDER IN ANY U	ached yet. You may add 5 more files. ort for the work, please upload letters of commitment in PDF format outlining their commitment. DO NOT PLOADS.
cceptable file types: .pdf or any partners providing financial or in-kind supp ENTION THE PI BY NAME OR GENDER IN ANY U	ached yet. You may add 5 more files. ort for the work, please upload letters of commitment in PDF format outlining their commitment. DO NOT PLOADS.
cceptable file types: .pdf or any partners providing financial or in-kind supp ENTION THE PI BY NAME OR GENDER IN ANY U	ached yet. You may add 5 more files. ort for the work, please upload letters of commitment in PDF format outlining their commitment. DO NOT PLOADS.
cceptable file types: .pdf or any partners providing financial or in-kind supp IENTION THE PI BY NAME OR GENDER IN ANY U	ached yet. You may add 5 more files. ort for the work, please upload letters of commitment in PDF format outlining their commitment. DO NOT PLOADS.
cceptable file types: .pdf or any partners providing financial or in-kind supp IENTION THE PI BY NAME OR GENDER IN ANY U	ached yet. You may add 5 more files. ort for the work, please upload letters of commitment in PDF format outlining their commitment. DO NOT PLOADS.
cceptable file types: .pdf or any partners providing financial or in-kind supp JENTION THE PI BY NAME OR GENDER IN ANY U inancial Considerations and Project Ti	ached yet. You may add 5 more files. ort for the work, please upload letters of commitment in PDF format outlining their commitment. DO NOT PLOADS.
TENTION THE PIBY NAME OR GENDER IN ANY U Financial Considerations and Project Til Budget Form Instructions	ached yet. You may add 5 more files. ort for the work, please upload letters of commitment in PDF format outlining their commitment. DO NOT PLOADS.

- CAPITAL expenses can include: equipment, research supplies and reagents (no minimum dollar amount), purchase of hardware and software, equipment maintenance contract and service contract costs, data generated via core facilities.
- Capital Funding CATEGORIES are equipment, research supplies, reagents, chemical compounds, human tissue, animal models, hardware, software, data sets. If you haven't decided on vendors for supplies/reagents, you could list multiple ones. All capital assets must be made publicly available.
- GENERAL expenses can include: salary support with a fringe rate not to exceed 30% and project-related travel (up to 10%). These funds may cover indirect costs, up to 15% (or \$65,217 for an award of \$500,000). Additional Capital expenses may also be reimbursed from General Funding if the above Capital budget has been fully expensed. Use your organization's name in the Vendor column for salary support and indirect costs.
- General Funding CATEGORIES are salary support and indirect costs.
- Please note: Applicants should note that the total funding available across both disease areas is \$1 million, and individual award amounts will vary. Limited funding may be available to support salary expenses associated with selected projects. The amount awarded, if any, will be determined based on the specific needs and scope of the proposed work. Therefore, exact amounts cannot be guaranteed at this time.
- Non-allowable expenses include facility overhead such as utilities, other monthly subscription fees, and duplicate funding of already financed work.

MLSC Fiscal Year Ranges

FY27 dates: July 1, 2026 – June 30, 2027
 FY28 dates: July 1, 2027 – June 30, 2028

18. Breakdown of MLSC Expenditures: Please complete the MLSC Budget to show the detailed breakdown of expenditures for MLSC funds. DO NOT MENTION THE PI/co-PI BY NAME in the budget form. (required)

						-	
	А	В	С	D	E	F	
1	TOTAL GRANT Amount Requested	0					
2							

3	FY27 (7/1/26 – 6/30/27)						
4	FY27 CAPITAL Budget Details			or commas in FY Estimated Cost		List of Categories	
5	Vendor	Item / Description (be specific and ensure the description indicates a physical item rather than services or effort;	Category (only use the categories from the list to the rig	om Estimated Cost		Equipment	
6						Research supplies	
ign	ature						
							•
he M	ded Declaration **MLSC is making a concert unless specifically rec	erted effort to blind applications fr	om reviewers . As su	ch we are requesting that you	please do not mentio	on the PI by name or	
ther	e is mention of the PI's	quested. name or gender in the submitted a RL+F to search the application for t				-	
	•	s, and other uploads to ensure that t, please agree to the declaration b			uested.		
_	-	removed any mention of th d that if the PI's name or ge ineligible.	_	-		-	ly
á	asked. I understan application may be (required)	d that if the PI's name or ge	_	-		-	ly
ā	asked. I understan application may be (required)	d that if the PI's name or ge ineligible.	_	the application, except		-	ly
a a	asked. I understan application may be (required) norized Signature a	d that if the PI's name or ge ineligible. and Acceptance (required)	nder remains in	the application, except		-	ly
Auth	asked. I understan application may be (required) norized Signature a d a file. No files have be	d that if the PI's name or get ineligible. and Acceptance (required)	nder remains in	the application, except		-	ly
Auth Auth Accep	asked. I understan application may be (required) norized Signature a d a file. No files have be otable file types: .pdf, .jp	d that if the PI's name or ge e ineligible. and Acceptance (required) een attached yet. bg. jpeg. png	nder remains in	the application, except		-	
Auth Jploa Accep	asked. I understan application may be (required) norized Signature a d a file. No files have be otable file types: .pdf, .jp e upload an image of th	d that if the PI's name or get ineligible. and Acceptance (required) een attached yet. by, jpeg, png e signature.	nder remains in	the application, except		-	ly
Auth	asked. I understan application may be (required) dorized Signature a d a file. No files have be patable file types: .pdf, .jp e upload an image of th prized Representative S y that I am authorized to nat the statements made	d that if the PI's name or ge e ineligible. and Acceptance (required) een attached yet. bg. jpeg. png	Choose Files this application cond exhibits, are true	n behalf of the organization. I and correct to the best of my	certify that the above knowledge. The subi	e information is correct	
Face of the second seco	asked. I understan application may be (required) norized Signature a d a file. No files have be patable file types: .pdf, .jp e upload an image of the prized Representative S by that I am authorized to nat the statements made nation to the Massachus erstand that this Womer	d that if the PI's name or get ineligible. and Acceptance (required) een attached yet. ogjpeg, .png e signature. Signature and Acceptance o commit my organization and to me the herein, including all attachments at	Choose File this application country and exhibits, are true subject to prosecution be disqualified if it designed.	e n behalf of the organization. I and correct to the best of my on under the False Claims Law bes not contain all required in	certify that the above knowledge. The subive at M.G.L. c. 12, sectiformation or if the Ap	e information is correct mission of false ions 5A – 5O. oplicant does not meet	the
Auth Jploa Accep Please Author verify nform under	asked. I understan application may be (required) dorized Signature and a file. No files have be patable file types: .pdf, .jp. e upload an image of the prized Representative Soy that I am authorized to not the Massachus erstand that this Womer lility criteria required und the Program.	d that if the PI's name or get ineligible. and Acceptance (required) een attached yet. g, .jpeg, .png e signature. Signature and Acceptance o commit my organization and to made herein, including all attachments at eletts Life Sciences Center (MLSC) is a signature. I's Health Initiative Application may	Choose File Choose	n behalf of the organization. I and correct to the best of my on under the False Claims Law bes not contain all required in MLSC has sole discretion to d	certify that the above knowledge. The subive at M.G.L. c. 12, sectiformation or if the Ap	e information is correct mission of false ions 5A – 5O. oplicant does not meet	the
Jploa Accep Please Author under spec On be Massac On the comm n a pa proprii	asked. I understan application may be (required) d a file. No files have be potable file types: .pdf, .jp e upload an image of the porized Representative S by that I am authorized to nat the statements made nation to the Massachus erstand that this Womer lifty criteria required und the Program. iffically acknowledge the chalf of the applicant, I under chalf of the applicant of t	d that if the PI's name or get ineligible. and Acceptance (required) een attached yet. og, .jpeg, .png e signature. Gignature and Acceptance o commit my organization and to me a herein, including all attachments a setts Life Sciences Center (MLSC) is yes Health Initiative Application may der the Program. I also acknowledge	choose File Choose	n behalf of the organization. I and correct to the best of my on under the False Claims Law bees not contain all required in MLSC has sole discretion to do an andatory. d as part of this application marrials or data which fall within a price of the company, or regardification to design the company, or regardification to the company to the comp	certify that the above knowledge. The sub v at M.G.L. c. 12, sectiformation or if the Apletermine which applications applies to the MLSC that consing the competitive platerials or data to the ials and data as Confidence.	e information is correct mission of false ions 5A – 5O. Explicant does not meet icants receive benefits osure under the ated exemption set for sist of trade secrets or osition of such compa e MLSC that may be fidential. I also underst	the
Jploa Author Verify and the form under spectomer a paper or propriet the texas of the form	asked. I understan application may be (required) dorized Signature and a file. No files have be patable file types: .pdf, .jp. e upload an image of the prized Representative Soy that I am authorized to another the statements made and the statements made and the statements made and the program. The Program of the applicant, I used to see the program of the program. The Program of the program	d that if the PI's name or get ineligible. and Acceptance (required) een attached yet. gg. jpeg, png e signature. Signature and Acceptance o commit my organization and to me herein, including all attachments a setts Life Sciences Center (MLSC) is it's Health Initiative Application may der the Program. I also acknowledge that all of the terms and conditions of inderstand and acknowledge that all s. Law. "Public records" may not, he is Law. "Public records" may not he is Law. "Public records" may not he is law to the indicate	choose File Choose	n behalf of the organization. I and correct to the best of my on under the False Claims Law bees not contain all required in MLSC has sole discretion to do an andatory. d as part of this application marrials or data which fall within a price of the company, or regardification to design the company, or regardification to the company to the comp	certify that the above knowledge. The sub v at M.G.L. c. 12, sectiformation or if the Apletermine which applications applies to the MLSC that consing the competitive platerials or data to the ials and data as Confidence.	e information is correct mission of false ions 5A – 5O. Explicant does not meet icants receive benefits osure under the ated exemption set for sist of trade secrets or osition of such compa e MLSC that may be fidential. I also underst	the
Jploa Author Verify and the form under spectomer a paper or propriet the texas of the form	asked. I understan application may be (required) dorized Signature and a file. No files have be patable file types: .pdf, .jp. e upload an image of the prized Representative Soy that I am authorized to another the statements made and the statements made and the statements made and the program. The Program of the applicant, I used to see the program of the program. The Program of the program	d that if the PI's name or get ineligible. and Acceptance (required) een attached yet. g, jpeg, png e signature. Signature and Acceptance o commit my organization and to me a herein, including all attachments a retts Life Sciences Center (MLSC) is y's Health Initiative Application may der the Program. I also acknowledge that at Is Law. "Public records" may not, hot. I.G.L. Chapter 23I. Such exemption nation regarding the operation of a or (Trade Secrets Exemption). I und fall within the parameters of the Trials/data by the MLSC does not registered.	choose File Choose	n behalf of the organization. I and correct to the best of my on under the False Claims Law bees not contain all required in MLSC has sole discretion to do an andatory. d as part of this application marrials or data which fall within a price of the company, or regardification to design the company, or regardification to the company to the comp	certify that the above knowledge. The sub v at M.G.L. c. 12, sectiformation or if the Apletermine which applications applies to the MLSC that consing the competitive platerials or data to the ials and data as Confidence.	e information is correct mission of false ions 5A – 5O. Explicant does not meet icants receive benefits osure under the ated exemption set for sist of trade secrets or osition of such compa e MLSC that may be fidential. I also underst	the
Authorn Uploa Acception Indicate Uploa Authorn Uploa Acception Indicate Uploa Authorn Indicate I	asked. I understan application may be (required) dorized Signature and a file. No files have be patable file types: .pdf, .jr e upload an image of the prized Representative Soy that I am authorized to that the statements madnation to the Massachus erstand that this Womer dility criteria required under the Program. iffically acknowledge the end of the applicant, I under the program. iffically acknowledge the end of the applicant, I under the program. It is achieved the program of the program o	d that if the PI's name or get ineligible. and Acceptance (required) een attached yet. g, .jpeg, .png e signature and Acceptance commit my organization and to me herein, including all attachments a tetts Life Sciences Center (MLSC) is yet. Health Initiative Application may der the Program. I also acknowledge that at Is Law. "Public records" may not, he local. Chapter 231. Such exemption nation regarding the operation of a or (Trade Secrets Exemption). I und fall within the parameters of the Trials/data by the MLSC does not regulated.	choose File Choose	n behalf of the organization. I and correct to the best of my on under the False Claims Law bees not contain all required in MLSC has sole discretion to do an andatory. d as part of this application marrials or data which fall within a price of the company, or regardification to design the company, or regardification to the company to the comp	certify that the above knowledge. The sub v at M.G.L. c. 12, sectiformation or if the Apletermine which applications applies to the MLSC that consing the competitive platerials or data to the ials and data as Confidence.	e information is correct mission of false ions 5A – 5O. Explicant does not meet icants receive benefits osure under the ated exemption set for sist of trade secrets or osition of such compa e MLSC that may be fidential. I also underst	the

Timarany	(MassBio, MassMedic, etc.)
Other (spec	cify below)
Select for	the Principal Investigator to receive email notices and updates from the MLSC newsletter
You may unsubsc	ribe at any time.
questions or n	ard to reviewing your application and working together to advance research in women's health. If you have any need assistance, please get in touch with our team at WomensHealth@masslifesciences.com with the Women's we in the subject line.
questions or n	need assistance, please get in touch with our team at WomensHealth@masslifesciences.com with the Women's
questions or n Health Initiation	need assistance, please get in touch with our team at WomensHealth@masslifesciences.com with the Women's ve in the subject line.